Login to Your Account


DUBLIN – Kiadis Pharma NV filed an MAA with the EMA for ATIR-101, an adjunctive treatment for patients with hematological malignancies undergoing haploidentical (partially matched) allogeneic HSCT.

DUBLIN – Annexin Pharmaceuticals AB completed a listing on the First North exchange in Stockholm last week and is on track to begin clinical trials of its first-in-class therapy for inflammatory vascular disease by year-end.

DUBLIN – French biotech has a new source of cash for early stage ventures. Advent France Biotechnology has raised €64.75 million in a first closing of a new seed fund, which has a mandate to back first or best-in-class breakthrough innovations that address unmet medical needs.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: